Tema Heart & Health ETF (NASDAQ:HRTS) Short Interest Down 40.1% in June

Tema Heart & Health ETF (NASDAQ:HRTS) was the target of a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 583 shares, a drop of 40.1% from the June 15th total of 974 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 8,175 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of HRTS. Kestra Advisory Services LLC purchased a new stake in Tema Heart & Health ETF in the fourth quarter valued at approximately $27,000. JPMorgan Chase & Co. purchased a new position in Tema Heart & Health ETF during the 2nd quarter worth approximately $63,000. Citadel Advisors LLC purchased a new position in Tema Heart & Health ETF during the 3rd quarter worth approximately $243,000. Brookstone Capital Management acquired a new stake in Tema Heart & Health ETF during the 4th quarter valued at approximately $364,000. Finally, Royal Bank of Canada lifted its stake in Tema Heart & Health ETF by 8.8% during the 1st quarter. Royal Bank of Canada now owns 21,083 shares of the company’s stock valued at $710,000 after acquiring an additional 1,703 shares during the period.

Tema Heart & Health ETF Stock Up 1.3%

Shares of HRTS traded up $0.48 during trading hours on Thursday, reaching $36.46. 1,020 shares of the company traded hands, compared to its average volume of 6,062. The business has a fifty day moving average price of $34.78 and a 200-day moving average price of $34.82. Tema Heart & Health ETF has a 12-month low of $27.24 and a 12-month high of $37.57. The stock has a market capitalization of $54.33 million, a P/E ratio of 22.06 and a beta of 0.63.

Tema Heart & Health ETF Company Profile

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.